Actively Recruiting
Evaluating Venetoclax Plus Azacitidine for Adults with Acute Myeloid Leukemia in Colombia Real-World Practice
Led by AbbVie · Updated on 2026-08-26
70
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Acute myeloid leukemia AML is a common type of blood and bone marrow cancer in adults. This observational study in Colombia assesses how well venetoclax combined with azacitidine works for adults newly diagnosed with AML who are not eligible for intensive chemotherapy. The study aims to gather real-world information on this treatments effectiveness and safety. Participants will receive venetoclax tablets orally alongside azacitidine given either by subcutaneous or intravenous injection, following the approved local treatment guidelines. All participants are treated with this combination as prescribed by their doctors, with no placebo or alternative treatments involved. The treatment and monitoring will occur in routine clinical practice settings. Throughout the approximately 36-month study duration, participants will attend regular medical visits as part of standard care. Researchers will monitor overall survival up to 18 months, rates of remission, transfusion independence, event-free survival, treatment duration, adverse events, minimal residual disease status, and changes in quality of life. There is expected to be no extra burden beyond normal medical care visits during the study.
CONDITIONS
Brief Title
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
Research Team
A
Angela Duarte
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here